EBS Insider Trading Activity and SEC Form 4 Filings
EBS insider trading summary
Over the past 12 months, insiders at Emergent BioSolutions Inc. (EBS) reported 14 sales worth $1.2M by 6 insiders and no open-market purchases on SEC Form 4. Net insider selling was $1.2M.
Latest EBS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 7, 2026 | Donald W DeGolyer | Director | Sell | $126K (17,800 @ $7.09) |
| Oct 1, 2026 | Paul Anthony Williams | SVP, Products Business | Sell | $20K (3,000 @ $6.53) |
| May 1, 2026 | Sujata Tyagi Dayal | Director | Sell | $9K (980 @ $8.94) |
| May 1, 2026 | Donald W DeGolyer | Director | Sell | $9K (954 @ $8.96) |
| May 1, 2026 | Kathryn C Zoon | Director | Sell | $9K (1,057 @ $8.97) |
| May 1, 2026 | Kathryn C Zoon | Director | Sell | $135K (16,145 @ $8.36) |
| May 1, 2026 | Sujata Tyagi Dayal | Director | Sell | $107K (12,781 @ $8.36) |
| May 1, 2026 | Donald W DeGolyer | Director | Sell | $121K (14,527 @ $8.36) |
| Apr 30, 2026 | Keith Katkin | Director | Sell | $128K (15,481 @ $8.28) |
| Apr 1, 2026 | Paul Anthony Williams | SVP, Products Business | Sell | $34K (4,000 @ $8.44) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.